Location: Germany, Bavaria, Munich
Employees: 1-10
Investment Type: Venture Capital
Portfolio 26
| Date | Name | Website | Total Raised | Location |
| 21.07.2026 | Immitra Bi... | immitrabio.com | $3.15M | Switzerlan... |
| 15.10.2025 | Tubulis | tubulis.com | $629.54M | Germany |
| 23.02.2024 | Altavo | altavo.eu | $5.39M | - |
| 09.02.2024 | Chipmetric... | chipmetrics.com | $2.61M | Finland, M... |
| 12.07.2023 | ReCatalyst | recatalyst.si | $1.87M | Slovenia, ... |
| 03.07.2023 | EBAMed | eba-med.com | $18.62M | Switzerlan... |
| 24.03.2023 | Lunaphore | lunaphore.ch | $82.86M | Switzerlan... |
| 28.09.2022 | core-sensing.de | - | Germany, H... | |
| 27.09.2022 | Avelo | avelolife.com | $3.86M | Switzerlan... |
| 16.06.2022 | Invasight | invasight.com | $4.61M | Switzerlan... |
Show more
Persons 10
| Date | First Name | Last Name | Title | Location | |||
| - | Michael | Pauer | Chief Inve... | linkedin.c... | - | - | - |
| - | Simon | Schild von... | Investment... | linkedin.c... | - | - | - |
| - | Matthias | Schrader | Legal Coun... | linkedin.c... | - | - | - |
| - | Sandra | Cvetkovic | Finance Ma... | linkedin.c... | - | - | - |
| - | Cédric | Barra | Senior Inv... | linkedin.c... | - | - | - |
| - | Patrizia | Schützenhö... | Chief Exec... | linkedin.c... | - | - | - |
| - | Eliane | Wiedmer | Investment... | linkedin.c... | - | - | - |
| - | Mirco | Müller | Junior Inv... | linkedin.c... | - | - | - |
| - | Olivia | Adler | Team Assis... | linkedin.c... | - | - | - |
| - | Paul | Sunzenauer | Junior Inv... | linkedin.c... | - | - | - |
Mentions in press and media 38
| Date | Title | Description |
| 27.07.2026 | Biotech Disruptor Immitra Bio Secures CHF 2.4 Million for In-Vivo Gene Editing | Immitra Bio secured CHF 2.4 million pre-seed funding. The Geneva biotech develops a scalable in-vivo gene editing platform. Its lead candidate, IB-003, offers a potential one-time cure for inherited anemia. This mutation-agnostic technology... |
| 21.07.2026 | ImmitraBio secures CHF 2.4 million in pre-seed funding | Immitra Bio is developing a platform for scalable, one-time curative in-vivo gene editing therapies based on its novel mutation agnostic gene editing technology and digital target identification platform. The company’s approach is designed... |
| 03.11.2025 | Tubulis: Second Tranche Of €344 Million Series C Closed To Advance ADC Pipeline | Tubulis announced the second and final closing of its Series C financing round, bringing the total raised to €344 million ($401 million). The round included new investors Fidelity Management & Research Company, Janus Henderson Investors... |
| 30.10.2025 | Tubulis Announces Second Closing of Series C Bringing Total Raised to €344M (US $ 401M) | MUNICH, GERMANY, October 30, 2025 – Tubulis today announced a second and final closing of its Series C round totaling €344M (US $401M). The second closing brought in additional new investors Fidelity Management & Research Company, Janu... |
| 16.10.2025 | German biotech Tubulis secures record-breaking €308M Series C | Tubulis, a pioneer in the development of uniquely matched antibody-drug conjugates (ADCs), this week announced the successful closing of a €308 million Series C financing round. This landmark round marks the largest Series C raised by a Eur... |
| 15.10.2025 | Tubulis Raises €308 Million Series C to Accelerate Clinical Development of Lead ADC Candidate TUB-040 and Expand Pipeline | • USD 361 million round represents the largest Series C for a European biotechnology company and the largest financing for a private ADC developer globally • Round led by Venrock Healthcare Capital Partners with participation from other new... |
| 15.10.2025 | Tubulis Raises €308M In Series C Funding | Tubulis, a Munich, Germany-based oncology company, closed a €308 million (USD 361m) Series C financing. The round was led by Venrock Healthcare Capital Partners with participation from additional new investors Wellington Management and Asce... |
| 15.10.2025 | Tubulis: €308 Million Series C Secured To Advance Clinical Development Of Lead ADC Candidate TUB-040 | Tubulis announced the closing of a €308 million ($361 million) Series C financing round aimed at accelerating the clinical development of its lead antibody-drug conjugate (ADC) candidate, TUB-040. The round was led by Venrock Healthcare Cap... |
| 24.01.2025 | EBAMed completes Series A with EUR 1.6M investment | The new funds were raised from CDP Venture Capital as part of the PNRR (Piano Nazionale di Ripresa e Resilienza) and the Next Generation EU initiative. This significant new milestone brings the startup led by CEO Marina Izzo to the maximum... |
| 09.10.2024 | Lymphatica Medical raises €17.9 million in series B Funding | First of its kind, LymphoDrain is easy to implant subcutaneously through a minimally invasive technique and it’s intended to provide unprecedent benefits to patients by locally and actively replacing the lymphatic vessels draining function... |
Show more